Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Pareto Securities in its capacity as Sole Manager and Bookrunner in connection with a directed share issue
Mandate

Vinge has advised Pareto Securities in its capacity as Sole Manager and Bookrunner in connection with a directed share issue

November 12, 2020 Capital Markets and Public M&A

Vinge has advised Pareto Securities in its capacity as Sole Manager and Bookrunner in connection with a directed share issue in the pharmaceutical company Xbrane Bipharma, whereby Xbrane Biopharma receives gross proceeds of approximately SEK 200 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue was, inter alia, to carry out a capital raise in a timely and cost-effective manner, further diversifying and strengthening Xbrane Biopharma´s shareholder base, as well as finance the continued development of Xbrane Biopharma´s product portfolio, including finalization of development and the regulatory process regarding Xlucane.

Vinge’s team has consisted of Jesper Schönbeck, Linnéa Sellström, Anders Sundin Lundberg and Lisa Malmborg.

Related

Vinge advises Setra Trävaror in conjunction with the sale of Malå Såg to HS Timber

 The Austrian company HS Timber Group has entered into an agreement to acquire 100 per cent of the shares in the Swedish wood processing company Malå Såg AB from Setra Trävaror AB, a subsidiary of Setra Group AB. The transaction remains subject to approval from the relevant public authorities.
October 29, 2025

Vinge has advised Advania on the acquisition of Visuell Teknik

 Advania has acquired Visuell Teknik, a Swedish provider of audiovisual and meeting technology solutions.
October 28, 2025

Vinge has advised Acrinova in connection with voluntary share redemption offering

 Vinge has advised Acrinova AB (publ) in connection with its voluntary share redemption offering. The offer comprised approximately one-third of the shares in Acrinova, and the acceptance rate reached approximately 97.34 percent, representing a redemption value of approximately SEK 367.4 million.
October 27, 2025